Like other ICI, avelumab can cause immune-related adverse events. Although rare, sarcoidosis-like granulomatous reactions have been described in patients on anti-CTLA-4 and anti-PD-1 immunotherapy.

A recent Swiss study suggests that a “wait and see” approach may be justified for younger horses with stable, small sarcoids because a large percentage of the tumors spontaneously regress without ...